Introduction
============

Breast cancer is a multifactorial disease that can be initiated by genetic mutations, chronic inflammation, exposure to toxic compounds, and abundant stress factors.^[@bib1]^ Despite of being a subject of concern across the world, the exact mechanism of breast cancer progression is not completely resolved yet.

Some genes of the keratin (*KRT*) family are important markers in reverse transcriptase polymerase chain reaction (RT--PCR)-mediated detection of tumors in the lymph nodes, peripheral blood, and bone marrows of breast cancer patients.^[@bib2],\ [@bib3]^ KRTs are intermediate filament proteins responsible for the structural integrity of epithelial cells and markers of the epithelial tissue.^[@bib4]^ Further, they are subdivided into cytokeratins and hair KRTs and also into low molecular weight acidic type I and high molecular weight basic or neutral type II.^[@bib5]^ KRTs are integrated in the cellular framework and interact with a range of cellular proteins including kinases, receptors, adaptors, and effectors. These interactions activate signaling networks that regulate cell migration, invasion, metastasis, cell cycle, and apoptosis.^[@bib4],\ [@bib6]^ For example, KRT8 and KRT18 bind with tumor necrosis factor receptor-2 in order to interact with other specific downstream proteins. Therefore, they affect tumor necrosis factor-dependent activation of downstream effectors such as c-JUN-NH2-kinase and NF-kB.^[@bib7]^ In addition, KRT17 binds to the adaptor protein 14-3-3σ to upregulate protein synthesis and cell growth via the AKT/mTOR pathway.^[@bib8]^

One of the smallest intermediate filament KRT proteins is a 40-kDa type I KRT, KRT19.^[@bib9]^ It contains a highly conserved α-helical central domain, essential for filament formation, and does not have a C-terminal non-helical tail domain.^[@bib10]^ In a previous study, *KRT19*-knocked out mice showed induced skeletal myopathy,^[@bib11]^ whereby KRT19 was shown to regulate breast cancer properties by activating the AKT signaling pathway.^[@bib12]^ However, recent studies have shown that modulation of *KRT19* expression led to contrasting effects on cell proliferation, survival, invasion, migration, and apoptosis, depending on the cancer cell type.^[@bib12],\ [@bib13],\ [@bib14]^ Therefore, extensive molecular studies on KRT19 are required to elucidate its role in cancer cells.

In this study, we demonstrate that knockdown of *KRT19* leads to increased proliferation, migration, invasion, drug resistance, and sphere formation in breast cancer cells. We report for the first time, a novel function of KRT19 in the NOTCH signaling pathway. Our data show that KRT19 directly interacts with β-catenin/RAC1 complex to regulate the stability and translocation of β-catenin. β-Catenin, in turn, binds to the *NUMB* promoter and accelerates its expression in breast cancer cells. Modulation of NUMB expression by KRT19 is therefore involved in the NOTCH pathway-mediated regulation of breast cancer and cancer stem cell properties.

Results
=======

Differential expression of the *KRT* family of genes in breast cancer cells
---------------------------------------------------------------------------

Using the Oncomine database ([www.oncomine.org](http://www.oncomine.org)), we compared the expression patterns of the *KRT* family of genes (*KRT1*--*20*) between normal and cancer tissues. Several of these genes showed altered expression in carcinoma compared with that in normal tissues ([Figure 1a](#fig1){ref-type="fig"} and [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}).^[@bib15]^ Interestingly, invasive breast carcinoma tissues showed relatively high *KRT18* and *KRT19* expression. In particular, the fold change for *KRT19* expression in invasive breast carcinoma versus normal breast tissue was significantly higher (*P*\<0.00001) than that for the other *KRT* genes ([Figure 1a](#fig1){ref-type="fig"} and [Supplementary Figure 1A](#sup1){ref-type="supplementary-material"}). This suggested strong correlation of *KRT19* expression with invasiveness of breast cancers. In order to confirm the specificity of our observation, we also examined the fold changes for the *KRT* genes in liver and colon cancer ([Figure 1a](#fig1){ref-type="fig"} and [Supplementary Figures 1B and C](#sup1){ref-type="supplementary-material"}).^[@bib16],\ [@bib17]^ The results concluded that indeed, *KRT19* expression specifically correlates with the invasiveness of breast carcinoma ([Figure 1a](#fig1){ref-type="fig"}).

Using RT--PCR, we next evaluated the expression of *KRT* genes in several cell lines, including MCF7, SKBR3 and MDA-MB231 (breast cancer); HepG2 (hepatocellular carcinoma); SH-SY5Y (neuroblastoma); HaCaT (immortalized human keratinocytes); and HEK293T (immortalized human embryonic kidney cells). In this case, too, *KRT19* was specifically overexpressed in the breast cancer cell lines MCF7, SKBR3, and MDA-MB231 ([Figure 1b](#fig1){ref-type="fig"}).

Knockdown of *KRT19* increases cell proliferation, migration, invasion, drug resistance, and sphere formation
-------------------------------------------------------------------------------------------------------------

As the breast cancer cells showed significantly high expression of *KRT19* compared with other *KRT* genes, we next assessed the effect of *KRT19* knockdown in MDA-MB231 and MCF7 cells. Compared with *KRT19* expression in the control (scrambled) short hairpin (sh)RNA-transduced cells, specific downregulation of *KRT19* expression (\~80%) was achieved in the *KRT19*-knocked down shKRT19 MDA-MB231 and shKRT19 MCF7 cells ([Figure 1c](#fig1){ref-type="fig"}).

Although the analysis of Oncomine database revealed that the *KRT19* expression positively correlates with the invasiveness of breast carcinoma ([Figure 1a](#fig1){ref-type="fig"}), knockdown of *KRT19* expression resulted in the increased proliferation of the breast cancer cells ([Figure 1d](#fig1){ref-type="fig"}). Migration and invasiveness of MDA-MB231 and MCF7 cells were also significantly increased upon *KRT19* knockdown ([Figures 1e and f](#fig1){ref-type="fig"}). Subsequent experiments in the presence of doxorubicin revealed significantly elevated drug resistance and its marker genes expression, including *ABCG2*, *ABCC1*, and *ABCB5*, in the *KRT19*-knocked down cells ([Figure 1g](#fig1){ref-type="fig"}). *KRT19* knockdown also significantly increased colony formation and expression of stemness markers (*OCT4*, *SOX2*, *NANOG*, and *c-MYC*) in both the shKRT19 MDA-MB231 and shKRT19 MCF7 cells ([Figures 1h and i](#fig1){ref-type="fig"}).

*KRT19* knockdown upregulates NOTCH signaling pathway by downregulating the expression of NUMB
----------------------------------------------------------------------------------------------

The unexpected findings that *KRT19* knockdown led to enhancement of breast cancer properties led us to explore the molecular mechanism behind the phenomenon. Recent report demonstrated that KRT19 had a role in modulation of NOTCH signaling pathway during the invasion of hepatocellular carcinoma.^[@bib13]^ More recently, a review article summarized on the crucial role of NOTCH and WNT signaling pathways and the cross-talk between NOTCH receptor and other oncogenic proteins such as Ras, c-Myc, and JAG1.^[@bib18],\ [@bib19]^ Actually, the WNT/β-catenin signaling pathway was reported to be positively or negatively cross-linked with the NOTCH pathway in cancer progression.^[@bib20],\ [@bib21],\ [@bib22],\ [@bib23],\ [@bib24],\ [@bib25]^ Therefore, we try to investigate whether the NOTCH and WNT signaling pathways are involved in molecular mechanism underlying the *KRT19*-silencing effect in breast cancer cells. First, in the *KRT19*-knocked down cells, we checked expression of the canonical WNT/β-catenin signaling target genes such as *AXIN2*, *TCF7*, *LEF1*, and *NUMB*. Although the canonical WNT signaling was generally suggested to be positively correlated with breast cancer cells,^[@bib26],\ [@bib27],\ [@bib28]^ our results showed that expression of WNT/β-catenin signaling target genes was significantly downregulated ([Figure 2a](#fig2){ref-type="fig"}). Furthermore, the TCF/LEF-responsive TOP- or FOP-FLASH transcription assay confirmed the downregulation of WNT/β-catenin signaling pathway in *KRT19*-silenced cells ([Figure 2b](#fig2){ref-type="fig"}). Next, we analyzed the expression of NOTCH signaling pathway-related genes, such as *NOTCH1*, *MAML1*, *RBPjK*, *HES1*, *H-RAS*, and *CCND1*. *KRT19* knockdown led to increased expression of NOTCH1 signaling pathway-interacting proteins, such as MAML1, RBPjK, and NOTCH1 itself ([Figure 2c](#fig2){ref-type="fig"}). In this context, several studies have shown that the NOTCH1 intracellular domain forms a complex with MAML1 and RBPjK that translocates to the nucleus to regulate target gene expression.^[@bib29],\ [@bib30],\ [@bib31],\ [@bib32]^ Concordantly, the expression of NOTCH1 target genes, such as *HES1*, *CCND1*, and *H-RAS,* were also increased in the *KRT19*-knocked down cells in this study ([Figure 2c](#fig2){ref-type="fig"}). Significantly, we observed that the expression of NUMB, a key inhibitory protein of the NOTCH signaling pathway,^[@bib33]^ was significantly downregulated upon *KRT19* knockdown ([Figures 2a and c](#fig2){ref-type="fig"}). As WNT/β-catenin pathway was reported to be interlinked with the NOTCH signaling pathway by NUMB,^[@bib34],\ [@bib35],\ [@bib36],\ [@bib37]^ we assumed that KRT19-mediated regulation of NUMB expression may be crucial for the cross-talk between the WNT and NOTCH signaling pathways. Furthermore, most Oncomine data analyses of normal breast tissue versus invasive ductal breast carcinoma supported the observation that *KRT19* expression correlates positively and inversely with that of *NUMB* and *NOTCH1*, respectively ([Figure 2d (ii--iv)](#fig2){ref-type="fig"}),^[@bib38],\ [@bib39],\ [@bib40]^ although a ductal breast carcinoma *in situ* versus invasive ductal breast carcinoma *in situ* data by Ma *et al.*^[@bib15]^ reported an opposite result ([Figure 2d (i))](#fig2){ref-type="fig"}.

We then examined the effects of inhibiting the NOTCH signaling pathway by treating shKRT19 cells with *N*-((3,5-Difluorophenyl)acetyl)-[l]{.smallcaps}-alanyl-2-phenyl)glycine-1,1-dimethylethyl ester (DAPT), a γ-secretase inhibitor. The results revealed a suppression of shKRT19-induced expression of NOTCH1 target genes ([Supplementary Figure 2A](#sup1){ref-type="supplementary-material"}). Moreover, DAPT treatment could relieve the shKRT19-mediated increase of cell proliferation ([Figure 3a](#fig3){ref-type="fig"}), migration ([Figure 3b](#fig3){ref-type="fig"}), invasion ([Figure 3c](#fig3){ref-type="fig"}), and sphere formation ([Figure 3d](#fig3){ref-type="fig"}) in MCF7 cells, but more markedly in the highly invasive and metastatic MDA-MB231 cells. This demonstrated that the NOTCH signaling pathway is crucial for *KRT19* knockdown to exert its cellular effects.

In addition, we tried to suppress the NOTCH signaling pathway by overexpressing NUMB in shKRT19 cells. We confirmed NUMB overexpression ([Supplementary Figure 2B](#sup1){ref-type="supplementary-material"}) and found that NOTCH intracellular domain and its target protein expression were downregulated in NUMB-overexpressing shKRT19 cells, compared with the shKRT19 cells ([Supplementary Figure 2B](#sup1){ref-type="supplementary-material"}). Notably, NUMB overexpression reversed the shKRT19-mediated increase of cell proliferation ([Figure 3e](#fig3){ref-type="fig"}), migration ([Figure 3f](#fig3){ref-type="fig"}), or sphere formation ([Figure 3g](#fig3){ref-type="fig"}), confirming that KRT19-mediated regulation of NOTCH signaling pathway and cancer properties is NUMB dependent.

KRT19 regulates nuclear localization of β-catenin
-------------------------------------------------

Next, we focused on the KRT19-dependent regulation of *NUMB* transcription. A previous study demonstrated that β-catenin translocates to the nucleus and binds the *TCF4* region of the *NUMB* promoter, enhancing transcription of the latter.^[@bib41]^ Based on this information, we investigated whether the β-catenin signaling pathway is involved in the KRT19-dependent regulation of *NUMB* transcription. The expression and phosphorylation (Ser 473 of AKT and Ser9 of GSK3β) of both AKT and GSK3β were not significantly altered in the *KRT19*-knocked down cells ([Figure 4a](#fig4){ref-type="fig"}), whereas the total amount of β-catenin and RAC1 proteins were slightly decreased ([Figure 4b](#fig4){ref-type="fig"}). However, the nuclear translocation of β-catenin was retarded upon *KRT19* knockdown ([Figure 4b](#fig4){ref-type="fig"}). Previously, several studies depicted an intriguing but controversial role of Rac1 in regulation of β-catenin nuclear localization.^[@bib42],\ [@bib43],\ [@bib44],\ [@bib45]^ Our results revealed that *KRT19* knockdown markedly suppressed nuclear translocation of RAC1, a binding partner of β-catenin that aids nuclear translocation of the latter.^[@bib43],\ [@bib46]^ Meanwhile, the cytoplasm presented higher amounts of β-catenin and RAC1 in the shKRT19 cells compared with that in control cells.

Nuclear translocation of β-catenin and RAC1 was then monitored by immunocytochemistry. This confirmed that both overall and nuclear β-catenin and RAC1 levels were significantly downregulated upon *KRT19* knockdown ([Figure 4c](#fig4){ref-type="fig"}), whereas that in the cytoplasm was increased. These results strongly suggested that regulation of β-catenin and RAC1 nuclear translocation is involved in the KRT19-dependent regulation of *NUMB* transcription.

KRT19 interacts with β-catenin and RAC1 to modulate nuclear translocation of the former
---------------------------------------------------------------------------------------

As RAC1 was reported to be a binding partner of β-catenin and may help nuclear translocation of β-catenin,^[@bib43],\ [@bib46]^ we performed coimmunoprecipitation experiments and revealed the interaction of KRT19 with β-catenin and RAC1 in the breast cancer cell lines ([Figure 5a](#fig5){ref-type="fig"}). However, *KRT19* knockdown significantly inhibited these interactions ([Figure 5b](#fig5){ref-type="fig"}). Upon treatment with the proteasome inhibitor MG132, β-catenin levels were increased and KRT19 levels were slightly augmented, whereas that of RAC1 was not significantly altered ([Figure 5c](#fig5){ref-type="fig"}). The interactions among KRT19, β-catenin and RAC1 were only slightly enhanced upon treatment with MG132, but markedly decreased upon *KRT19* knockdown even in presence of MG132 ([Figure 5d](#fig5){ref-type="fig"}). These results suggest the role of KRT19 in its interactions with β-catenin and RAC1.

Patient-derived CD133^high^/CXCR4^high^/ALDH1^high^ cancer stem-like cells (CSLCs) have decreased KRT19 expression and highly enhanced CSLC properties
------------------------------------------------------------------------------------------------------------------------------------------------------

Interestingly, we observed a marked suppression of *KRT19* expression in the CD133^high^/CXCR4^high^/ALDH1^high^ cancer stem-like cells (KU-CSLCs), which were prepared from chemo-treated breast cancer patients at the Konkuk University hospital ([Figure 6a](#fig6){ref-type="fig"}). Compared with the MDA-MB231 cells, KU-CSLCs showed lower *NUMB*, but higher *NOTCH1* and *HES1* (target of NOTCH1) expression ([Figure 6b](#fig6){ref-type="fig"}). Our data also demonstrated that KU-CSLCs have remarkably high sphere-forming capacity not only in sphere-forming media, but also in normal growth media ([Figures 6c and d](#fig6){ref-type="fig"}). KU-CSLCs also showed significantly enhanced expression of stemness and epithelial-to-mesenchymal transition markers, such as *NANOG*, *OCT4*, *SOX2*, and *N-cadherin*, with reduction in *p53* and *E-cadherin* levels ([Figures 6e and f](#fig6){ref-type="fig"}). Examination of KU-CSLCs using a xenograft mouse model revealed that these cells possess highly enhanced tumorigenic capacity *in vivo* ([Figures 6g, h, and i](#fig6){ref-type="fig"}).

As KU-CSLCs showed either very low or no KRT19 expression together with high NOTCH1 expression, similar to the shKRT19 MDA-MB231 cells, we next investigated whether KRT19 can regulate cancer stem cell properties by modulating the NOTCH signaling pathway. First, we treated the cells with DAPT (a NOTCH signaling inhibitor), which led to significant decrease in the expression of *NOTCH1* and *HES1*. However, DAPT did not affect *NUMB* expression in both the shKRT19 MDA-MB231 and KU-CSLCs ([Figure 6j](#fig6){ref-type="fig"}). Importantly, DAPT treatment suppressed proliferation and migration of KU-CSLCs, similar to that in the shKRT19 MDA-MB231 cells ([Figures 6k and l](#fig6){ref-type="fig"}; [Supplementary Figure 3A](#sup1){ref-type="supplementary-material"}). The cancer stem cell properties, including expression of stemness/epithelial-to-mesenchymal transition markers, and sphere-formation capacity of KU-CSLCs were also suppressed by DAPT treatment ([Supplementary Figures 3B and C](#sup1){ref-type="supplementary-material"}). KU-CSLCs showed *KRT19* and *NOTCH1* expression lower and higher, respectively, than the shKRT19 MDA-MB231 cells did ([Figure 6j](#fig6){ref-type="fig"}). The DAPT-mediated effect was also more marked in KU-CSLCs than in the shKRT19 MDA-MB231 cells ([Figures 6--l](#fig6){ref-type="fig"}). These results supported KRT19-dependent regulation of the NOTCH signaling pathway.

Either overexpression of *KRT19* or knockdown of *NOTCH1* led to decreased proliferation, migration, drug resistance, and sphere formation in the patient-derived KU-CSLCs
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Finally, to confirm the function of KRT19 in regulating the NOTCH signaling pathway, we either overexpressed *KRT19* or knocked down *NOTCH1* in the KU-CSLCs, both of which were successfully achieved ([Figure 7a](#fig7){ref-type="fig"}). Overexpression of *KRT19* increased *NUMB* and decreased *NOTCH1* and *HES1* expression. Meanwhile, *NOTCH1* knockdown led to decreased *HES1* expression, without affecting either *NUMB* or *KRT19* levels ([Figure 7a](#fig7){ref-type="fig"}). Importantly, both *KRT19* overexpression and *NOTCH1* knockdown significantly suppressed cell proliferation ([Figure 7b](#fig7){ref-type="fig"}) and migration ([Figure 7c](#fig7){ref-type="fig"} and [Supplementary Figure 4](#sup1){ref-type="supplementary-material"}). Drug resistance, expression of drug-resistance markers ([Figure 7d](#fig7){ref-type="fig"}), sphere formation ([Figure 7e](#fig7){ref-type="fig"}), and expression of stemness markers ([Figure 7f](#fig7){ref-type="fig"}) were also suppressed upon *KRT19* overexpression and *NOTCH1* knockdown in KU-CSLCs. These results strongly supported that KRT19 modulates the NUMB-dependent NOTCH signaling pathway in breast cancers and patient-derived CD133^high^/CXCR4^high^/ALDH1^high^/KRT19^low^ CSLCs, thus harboring potential clinical implications.

Discussion
==========

A prominent type I filament protein, KRT19 is abundantly expressed in epithelial tumor cells and is a marker for metastatic tumors.^[@bib47],\ [@bib48],\ [@bib49]^ Its overexpression in circulating tumor cells (CTCs) governs its crucial role in regulating their cancerous properties. However, a previous gene profiling microarray study showed that KRT19 is differentially expressed in different breast cancer cell lines. Moreover, its expression in these cell lines showed reciprocal correlation with their cancer properties (that is, high KRT19 with low CD44 and vice versa).^[@bib50]^ In fact, several reports have demonstrated the contradictory effects of KRT19 on cancer properties, depending on its concentration and the cell type involved.^[@bib12],\ [@bib13],\ [@bib14]^ For instance, cancer properties were positively regulated through the KRT19/HER2 signaling pathway by very high KRT19 levels in HER2-overexpressed breast cancer.^[@bib51]^ Meanwhile, negative regulation was observed in the BT474 and SKBR3 breast cancer cells, through the KRT19/Egr-1 signaling pathway, at either very low or no KRT19 concentration.^[@bib12]^ Another study demonstrated that overexpression of *KRT19* in the BT549 breast cancer cell line (expresses low levels of endogenous KRT19) inhibits cell proliferation and induces cell arrest by regulating endoplasmic reticulum stress and its related signaling pathway. Meanwhile, *KRT19* knockdown yielded the opposite results in MDA-MB231 cells (which express high endogenous KRT19).^[@bib52]^ Furthermore, KRT19 also has a critical role in the proliferation and invasiveness of some subtypes of hepatocellular carcinomas,^[@bib13],\ [@bib53]^ functioning as a cancer stem cell marker in the same.^[@bib14]^ Overall, therefore, the role of KRT19 in cancer (that is, progression or suppression) remains to be resolved through extensive molecular studies.

In this study, we compared the expression patterns of *KRT* genes (*KRT1*--*20*) in normal and cancer tissues, and found specific high expression of *KRT19* in invasive breast cancer. Although the analysis of Oncomine database suggested strong correlation of *KRT19* expression with breast cancer invasiveness, knockdown of *KRT19* expression yielded increased cell proliferation, migration, invasion, drug resistance and sphere formation in breast cancer cells, which showed specifically enhanced *KRT19* expression. Our results demonstrate that high KRT19 levels may negatively affect proliferation and invasiveness of breast cancers, though several *KRT* genes (including *KRT19*) are reported as important markers for RT--PCR-mediated detection of cancers.^[@bib2],\ [@bib3]^ Importantly, *KRT19* expression was markedly suppressed in CD133^high^/CXCR4^high^ /ALDH1^high^ KU-CSLCs, which were prepared from chemo-treated breast cancer patients and showed abnormally elevated cell proliferation, migration, invasion, drug resistance, and sphere formation. In addition, *KRT19* overexpression in KU-CSLCs significantly suppressed their proliferation and migration ([Figure 7](#fig7){ref-type="fig"}), strongly supporting the anticancer/-CSLC function of KRT19.

The underlying molecular mechanism of KRT19 must be studied in order to understand better its functions in cancer cells. We report here, for the first time, a novel function of KRT19 in regulation of the NUMB-dependent NOTCH signaling pathway in breast cancer cells and CSLCs. NOTCH possesses oncogenic functions in several cancers, including leukemia and breast cancer,^[@bib54],\ [@bib55]^ and also regulates differentiation, proliferation, and growth of either cancer or stem cells.^[@bib56],\ [@bib57]^ Several studies also reported that NUMB-mediated regulation of the NOTCH signaling pathway modulates migration and invasion in different tumor cell types, including pancreatic,^[@bib58]^ ovarian,^[@bib59]^ and prostate.^[@bib60]^ NUMB also suppresses the NOTCH signaling pathway through proteolytic degradation of the NOTCH intracellular domain.^[@bib33]^ Furthermore, it regulates asymmetric cell division in mammalian development, cell adhesion and migration, as well as a number of signaling pathways.^[@bib35],\ [@bib61],\ [@bib62]^ Recent studies confirmed that the NOTCH signaling pathway is suppressed by overexpressed NUMB, suggesting that the latter acts as a tumor suppressor.^[@bib63],\ [@bib64]^ In the current study, *KRT19* knockdown-mediated suppression of NUMB expression led to increased NOTCH activity as well as NOTCH-dependent proliferation of breast cancer cells. Importantly, we demonstrated the crucial function of KRT19 in modulating the NOTCH signaling pathway and related cancer and CSLC properties, not only in breast cancer cells (MCF7 and MDA-MB231), but also in patient-derived CD133^high^/CXCR4^high^/ALDH1^high^/KRT19^low^ CSLCs.

At the molecular level, we demonstrated that KRT19 functionally interacts with the β-catenin-RAC1 complex, and promotes stability and nuclear translocation of the same. This regulation is crucial to the expression of NUMB, which suppresses the NOTCH signaling pathway. NUMB, a direct transcriptional target of the WNT signaling pathway, could ubiquitously degrade NOTCH intracellular domain and negatively regulate NOTCH signaling pathway.^[@bib35],\ [@bib36]^ Furthermore, previous studies demonstrated that inhibition of NUMB resulted in activation of NOTCH signaling pathway.^[@bib65],\ [@bib66]^ KRT19-mediated regulation of NUMB expression may be crucial for cross-linking and balancing of the canonical WNT and NOTCH signaling pathways, which will be characterized in detail in the further study. Essentially, our results demonstrated that silencing of *KRT19* expression inhibits formation of the β-catenin-RAC1 complex, and positively regulates NOTCH signaling by inhibiting β-catenin-mediated *NUMB* transcription. A recent study reported that the canonical WNT signaling pathway upregulates NUMB expression in myoblasts. This occurs when β-catenin binds to regulatory regions of the *NUMB* promoter at *TCF* sites 545 and 640 bp upstream of the transcriptional start site.^[@bib41]^ Moreover, RAC1 genetically interacts with β-catenin and controls its nuclear localization to the *TCF3/4* sites of the target gene promoter.^[@bib43],\ [@bib44]^ Furthermore, active/inactive Rac1 could shift Rac1--β-catenin complexes toward the nucleus.^[@bib67],\ [@bib68],\ [@bib69]^ In addition, a protein complex composed of RAC1B, β-catenin and disheveled functions to enhance nuclear translocation of transcription factors required for increased interaction with the target promoters.^[@bib46]^ These studies corroborate our proposed mechanism that KRT19 directly interacts with the β-catenin-RAC1 complex to promote nuclear translocation of β-catenin and activate *NUMB* transcription.

Our data also showed that the effect of *KRT19* knockdown is more marked in the highly invasive and metastatic MDA-MB231 breast cancer cells ('basal\' type, triple negative (ER^−^PR^−^HER2^−^)), compared with that in the MCF7 cells ('luminal\' type, ER^+^PR^+^).^[@bib70]^ A previous report demonstrated that KRT19^+^ CTCs differentially affect breast cancer patients with ER-negative and -positive (basal- and luminal-like CTCs, respectively) tumors. Despite of similar KRT19 expression in CTCs of both tumor types, the clinical outcomes of prognosis differed depending on the ER expression, especially at the early stages.^[@bib2]^ Specifically, breast cancer patients with ER^−^ CTCs showed poor prognosis than those with ER^+^ CTCs.^[@bib2],\ [@bib71],\ [@bib72],\ [@bib73],\ [@bib74],\ [@bib75],\ [@bib76]^ Concomitantly, in this study, KRT19-dependent regulation of the NOTCH signaling pathway significantly modulated the cancer/CSLC properties of KU-CSLCs, which are ER^−^. ERα is known to increase the expression of KRT19, (ref. [@bib77], [@bib78], [@bib79], [@bib80]) and NOTCH signaling activity is higher in ERα^−^ cells than in ERα^+^ ones.^[@bib81],\ [@bib82]^ Furthermore, one previous study has reported an important and differential role of NOTCH signaling pathway in regulation of cancer/CSLC properties either in ERα^+^ or ERα^−^ and triple negative breast cancer.^[@bib83]^ Further studies are required to elucidate the effects of ER, PR, and HER2 expression on KRT19-mediated regulation of the NOTCH signaling pathway as well as cancer/CSLC properties.

In conclusion, our study shows that KRT19 directly interacts with the β-catenin-RAC1 complex, and stabilizes ubiquitination and proteasomal degradation of β-catenin to increase its nuclear translocation. *NUMB* expression is enhanced in the process, which then downregulates NOTCH signaling; its target genes; and consequently, cell proliferation, migration, invasion, drug resistance, and sphere formation ([Figure 8](#fig8){ref-type="fig"}). Our data might be crucial to understand the molecular basis of KRT19- and NOTCH-mediated regulation of cancer/CSLC properties, and might hold potential clinical implications as well.

Materials and methods
=====================

Cell culture
------------

Human cell lines for breast cancer (MDA-MB231, SKBR3, and MCF7), hepatocellular carcinoma (HepG2), neuroblastoma (SH-SY5Y), immortalized human keratinocytes (HaCaT), and embryonic kidney cells (HEK293T) are obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). All cell lines and breast cancer patient-derived CD133^high^/CXCR4^high^/ALDH1^high^ high sphere-forming KU-CSLCs were cultured in either high glucose-Dulbecco\'s Modified Eagle Medium or Roswell Park Memorial Institute medium (DMEM or RPMI) 1640 (Sigma-Aldrich, Saint Louis, MO, USA) supplemented with 10% fetal bovine serum. Cells were maintained in a humidified incubator at 5% CO~2~ and 37 °C. All cell lines were authenticated by short tandem repeat profiling and were tested for mycoplasma contamination using *BioMycoX* Mycoplasma PCR Detection Kit (Cat. No. CS-D-25) (Cellsafe, Yeongtong-gu, Suwon, Republic of Korea).

CD133^high^/CXCR4^high^/ALDH1^high^ KU-CSLCs were prepared from breast tumor tissue specimens, which were collected from chemo-treated patients who underwent mammotomy for breast tumors at the Breast Cancer Center, Konkuk University Hospital, Seoul. The study was performed with approval from the Institutional Review Board (IRB, KUH 1020003).

Knockdown and overexpression of *KRT19* and *NOTCH1*
----------------------------------------------------

Sense and antisense oligonucleotides for control (scrambled), *KRT19*- (shKRT19),^[@bib12]^ and *NOTCH1*-specific (shNOTCH1) shRNA,^[@bib84]^ containing *BamH*I and *EcoR*I restriction sites, were annealed by using annealing buffer (Tris-EDTA buffer (pH 8), 100 m[M]{.smallcaps} NaCl (Sigma-Aldrich)). Next, the annealed oligonucleotides were inserted into the pGreenPuro lentiviral expression vector (System Biosciences, Mountain View, CA, USA) to construct *KRT19*-, *NOTCH1*-knocked down, or control vectors. The oligonucleotide sequences of the shRNAs are listed in [Table 1](#tbl1){ref-type="table"}.

For overexpression of *KRT19*, its complete coding sequence was cloned into the pGEM-T Easy vector (Promega, Madison, WI, USA) using the primers listed in [Table 1](#tbl1){ref-type="table"}. The complete coding sequence was further subcloned into the pCDH-EF1-MCS-T2A-copGFP lentiviral vector (System Biosciences) using *Xba*I and *EcoR*I restriction enzymes and the primers listed in [Table 1](#tbl1){ref-type="table"}.

HEK293T cells were transfected with the specific lentiviral vector and viral packaging plasmids, RRE and REV, using calcium phosphate transfection protocol. After 72 h of incubation at 5% CO~2~ and 37 °C, viruses were collected and concentrated using an ultracentrifuge (Optima L-90K, Beckman Coulter Inc., CA, USA). MDA-MB231 and MCF7 cells were then infected with either scrambled shRNA or shKRT19 lentiviruses, whereas KU-CSLCs were infected with either scrambled shRNA, shNOTCH1 or KRT19-expressing lentiviruses and incubated overnight at 5% CO~2~ and 37 °C. For virus infection, \~8.0 × 10^8^ IU/ml viral particles were used to get stably expressing cells. To measure virus titer, we use the following equation, titer in IU/ml=(((no. of cells at starting time) × (dilution factor) × (percent infection))/(volume virus solution added expressed in ml)) as described previously.^[@bib85]^ Next, the media were substituted with normal growth media (high glucose DMEM/RPMI 1640 with 10% fetal bovine serum). The virus infection efficiency was calculated to be \<95%, and knockdown or overexpression was assessed by RT--PCR and western blot analyses.

For *NUMB* overexpression, MDA-MB231 and MCF7 KRT19-knocked down cells were incubated overnight at a density of 2 × 10^5^ cells per wells in 24-well culture plate and transfected with the expression vectors (pEF-BOS-myc-NUMB and control vector, kind gifts from professor Hee-Sae Park (Chonnam National University) using Lipofectamine in 1:3 ratio (Invitrogen, Carlsbad, CA, USA). After 48 h of post-transfection, half of cells were harvested for western blotting and the remained cells were used for cell proliferation, migration and sphere-formation analyses.

Total RNA extraction and RT--PCR analyses
-----------------------------------------

Total RNA was extracted from the cells using Easy-Blue total RNA extraction kit (iNtRON Biotechnology, Republic of Korea) according to the manufacturer\'s instructions. The concentration of total RNA was measured using Nanodrop (ND1000) spectrophotometer (Nanodrop Technologies Inc., Wilmington DE, USA). Subsequently, 2 μg of total RNA was used for cDNA synthesis with M-MLV reverse transcriptase (Promega) according to the manufacturer\'s instructions. Sequences of the primers used are given in [Table 2](#tbl2){ref-type="table"}. After the PCR reaction, the products were analyzed on either 1 or 1.5% agarose gels. Quantitative real-time RT--PCR was done using a PTC-200 thermal cycler with Chromo4 optical detector (MJ Research/Bio-Rad, CA, USA) using Fast SYBR Green Master Mix (Applied Biosystems, Stockholm, Sweden). mRNA expression was normalized to that of the control housekeeping gene, *GAPDH* as described previously.^[@bib86]^

Western blot analysis
---------------------

Cells were lysed using lysis buffer (1% Triton X-100 (Sigma-Aldrich), 100 m[M]{.smallcaps} Tris-HCl (pH 7.5), 10 m[M]{.smallcaps} NaCl, 10% glycerol (Amresco, Solon OH, USA), 50 m[M]{.smallcaps} sodium fluoride (Sigma-Aldrich), 1 m[M]{.smallcaps} phenylmethylsulfonyl fluoride (PMSF; Sigma-Aldrich), 1 m[M]{.smallcaps} p-nitrophenyl phosphate (Sigma-Aldrich), and 1 m[M]{.smallcaps} sodiumorthovanadate (Sigma-Aldrich)) and the lysates were centrifuged at 13 000 rpm for 15 min at 4 °C. The protein supernatant was quantified using Bradford protein assay reagent (BioRad), and the proteins were resolved by either 10 or 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis. The separated proteins were then transferred onto nitrocellulose membranes (Bio-Rad). After blocking with 5% skimmed milk in Tris-buffered saline for 1 h, the membranes were incubated with appropriate primary antibodies against KRT19 (SC-53258, 1:500), cyclinD1 (SC-717, 1:1000), H-RAS (SC-35, 1:1000), NUMB (SC-15590, 1:200), β-catenin (SC-7199, 1:2000), RAC1 (SC-217, 1:500), AKT (SC-1619, 1:1000), phospho (p)-AKT (SC-16646-R, 1:1000), GSK3β (SC-9166, 1:1000), p-GSK3β (SC-11757, 1:1000), HES1 (SC-13844, 1:500), actin (SC-1616, 1:1000) (Santa Cruz Biotechnology, Dallas, TX, USA), and intracellular domain (ab83232, 1:1000) (Abcam, Cambridge, UK) overnight at 4 °C. This was followed by a 2 h incubation with anti-mouse (SC-2005), -goat (SC-2020), -rabbit (SC-2004) or --rat (SC-2006) IgGs (1:1000) tagged with horse radish peroxidase (Santa Cruz Biotechnology). Protein signals were detected using an enhanced chemiluminescence kit (Amersham Bioscience, Piscataway, NJ, USA) as described previously.^[@bib86]^

Cell proliferation, invasion, wound-healing/migration and drug-resistance assays
--------------------------------------------------------------------------------

Cell proliferation was performed as described.^[@bib87]^ For analysis of cell proliferation, 2 × 10^4^ cells/well were seeded in 12-well dishes. For 4 days, the cells (in triplicates) were trypsinized and enumerated every 24 h using a hemocytometer.

Invasion assay was conducted using CytoSelect 96-Wells Cell Invasion Assay Kit (Cell Biolabs Inc., CA, USA) as described.^[@bib88]^ Cells (1 × 10^5^) were seeded in 96-well culture plates, and the assay was conducted according to the manufacturer\'s protocol.

Wound-healing/migration assay was performed as described.^[@bib89]^ In brief, 1 × 10^6^ cells were seeded in 60-mm plates and grown until 90% confluent. Prior to the experiment, the cells were incubated with mitomycin C (10 μg/ml), which inhibits cell division. After 2--3 h of incubation at 5% CO~2~ and 37 °C, the cell monolayer was wounded with a 200 μl pipette tip. Cells were then washed thrice with phosphate-buffered saline (PBS), and images of this wound were acquired by Nikon eclipse TE2000-U microscopy (Nikon Instruments Inc., Melville, NY, USA) at various time points (0, 12 and 24 h).

Drug-resistance analysis was performed as described previously.^[@bib90]^ In brief, 1 × 10^5^ cells were seeded in 12-well dishes. Following overnight incubation at 5% CO~2~ and 37 °C, they were treated with 0.5 μ[M]{.smallcaps} doxorubicin and incubated for another 48 h. They were then enumerated and represented as percent (%) of surviving cells.

Sphere-formation assay
----------------------

Cells (1 × 10^4^) were cultured and suspended in either growth medium (DMEM/RPMI 1640 (Sigma-Aldrich) with 10% fetal bovine serum) or SM (sphere-formation medium: serum-free DMEM/F12 supplemented with B27-supplement (1:50; Invitrogen)) supplemented with 20 ng/ml epidermal growth factor (Sigma-Aldrich), 10 μg/ml insulin (Invitrogen), and 0.4% bovine serum albumin (Sigma-Aldrich), using non-coated plates. To propagate the spheres *in vitro*, they were collected by gentle centrifugation, dissociated into single cells as described previously,^[@bib91],\ [@bib92]^ and then cultured to obtain next-generation spheres. Spheres from MDA-MB-231, MCF7 cells, and KU-CSLCs were collected after 5 days of culture, stained with crystal violet (Sigma-Aldrich) and photographed by Nikon eclipse TE2000-U microscopy (Nikon Instruments Inc.) prior to colony counting.

Luciferase reporter assay
-------------------------

For luciferase reporter assays, 1 × 10^5^ MDA-MB-231 or MCF7 cells were seeded in 12-well plate and transiently transfected with either 200 ng of TOP- or FOP-FLASH (kind gifts from professor Keun Il Kim (Sookmyung Women\'s University) by using Lipofectamine 2000 reagents (1:3 ratio) (Invitrogen).^[@bib93]^ After 48 h post transfection, the luciferase activity using a luciferase assay system (Promega) was analyzed by a luminometer (Veritas microplate luminometer, Turner Biosystems, CA, USA) and transfection efficiency was normalized by β-galactosidase expression.

Immunocytochemistry
-------------------

Immunocytochemistry was performed as described previously.^[@bib86]^ In brief, Cells (1 × 10^4^) were seeded and incubated for 24 h at 5% CO~2~ and 37 °C. They were then washed with PBS, fixed with 4% paraformaldehyde, and permeabilized with 0.2% Triton X-100 for 10 min. The fixed cells were blocked with 10% normal goat serum (Vector Lab, Burlingame CA, USA) in PBS for 1 h, followed by incubation with primary antibody, diluted in PBS, overnight at 4 °C. After washing thrice with PBS, the cells were incubated with secondary antibody for 1 h and washed with PBS again. Nuclei were stained with TOPRO3 (10 μg/ml; Invitrogen) for an additional 10--15 min. Next, the cells were washed thrice with PBS. Immunofluorescence was monitored with a Leica TCS SP5 II laser scanning confocal microscope (Leica Microsystems, Wetzlar, Germany).

Cell fractionation
------------------

Cell fraction was performed as described previously.^[@bib12]^ In brief, cells were washed with ice-cold PBS and harvested in cytoplasmic extraction buffer (10 m[M]{.smallcaps} HEPES (pH 7.9; Sigma-Aldrich) 10 m[M]{.smallcaps} KCl (Sigma-Aldrich), 0.1 m[M]{.smallcaps} EDTA (Sigma-Aldrich), 0.1 m[M]{.smallcaps} EGTA (Sigma-Aldrich), 1 m[M]{.smallcaps} dithiothreitol (DTT; Invitrogen), and 0.5 m[M]{.smallcaps} PMSF (Sigma-Aldrich)). The cell suspension was agitated for 10 min at 4 °C, followed by further agitation for another 10 min at 4 °C with NP-40 (final 0.5% (Sigma-Aldrich)). They were then centrifuged at 13 000 rpm at 4 °C for 5 min. The supernatant was collected as the cytoplasmic fraction. Next, the nuclear pellets were washed 2--3 times with cold PBS and resuspended in nuclear extraction buffer (20 m[M]{.smallcaps} HEPES (pH 7.9), 400 m[M]{.smallcaps} NaCl, 1 m[M]{.smallcaps} EDTA, 1 m[M]{.smallcaps} EGTA, 1 m[M]{.smallcaps} DTT, and 1 m[M]{.smallcaps} PMSF). The suspended sample was agitated for 10 min at 4 °C, followed by centrifugation at 13 000 rpm at 4 °C for 10 min. The supernatants were then collected as the nuclear fraction.

Coimmunoprecipitation analysis
------------------------------

To investigate the protein--protein interactions, cell lysates (400 μg) were precleaned with 50 μl Protein A/G sepharose (Santa Cruz Biotechnology) for 2 h with agitation at 4 °C, and then centrifuged at 3000 rpm for 1 min. The supernatant was collected and incubated with either primary antibodies or normal rabbit/mouse IgG overnight at 4 °C. Next, another 50 μl of protein A/G sepharose was added and incubated for another 4 h at 4 °C. The pellet was then washed thrice with cell lysis buffer, and the immunoprecipitated proteins were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis and subsequent western blotting as described previously.^[@bib12]^

*In vivo* tumorigenicity analysis
---------------------------------

Either MDA-MB231 cells or KU-CSLCs (100, 1000 or 10 000) were injected subcutaneously into the lower flanks of 5-month-old female severe combined immunodeficient mice,^[@bib94]^ purchased from KRIBB (Korean Research Institute of Bioscience and Biotechnology, Republic of Korea). The mice were monitored for tumor formation and growth. The mice were killed 4 weeks post tumor formation, and the tumor weights and volume determined as described previously.^[@bib95]^ For statistical analysis, at least five mice were used in each group. During the study, the mice were excluded if they died or did not form tumor. According to body weight of mice, they were evenly divided into two groups but not randomly. During the experiment, investigator was blinded for allocation of group. The mice were cared for and treated in compliance with the institutional guidelines (KU11039).

Statistical analyses
--------------------

All experiments were conducted independently at least thrice. Data were analyzed using GraphPad InStat version 3 program (Graphpad, Sandiego, CA, USA) and presented as average values±s.d. Statistical analyses were done using two-tailed Student\'s *t*-test for two groups and, for multiple comparison test, analysis of variance was performed with adjusting Tukey--Kramer to compare treated versus control. A *P*-value\<0.05 was considered statistically significant.
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###### 

Click here for additional data file.

###### 

Knockdown of *KRT19* increases cell proliferation, migration, invasion, drug resistance, and sphere formation in breast cancer cell lines. Data were obtained from three independent experiments and presented as average values±s.d. (\**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001). (**a**) Expression fold changes for *KRT* genes (*KRT1--20*) in invasive ductal breast carcinoma versus (vs) normal breast tissue, hepatocellular carcinoma vs normal liver tissue, and colon adenocarcinoma vs normal colon tissue, as obtained from the Oncomine database. (**b**) mRNA expression of *KRT* genes in breast cancer (MCF7, SKBR3, and MDA-MB231), hepatocellular carcinoma (HepG2), neuroblastoma (SH-SY5Y), immortalized human keratinocytes (HaCaT), and immortalized human embryonic kidney (HEK293T) cell lines. Bands for *KRT*s in **b** were quantified by scanning densitometry and normalized to that of *GAPDH* (right panel). (**c**) *KRT19* expression analyzed by reverse transcription polymerase chain reaction (RT--PCR) and western blot analysis. Either *GAPDH* or actin expression was used as control. Both KRT19 mRNA and protein expression were quantified by scanning densitometry and normalized to that of *GAPDH* and actin, respectively (right panel). (**d**) Effect of *KRT19* knockdown on cell proliferation analyzed by cell counting. Cells were counted up to 4 days. (**e**) Migration capacity of the indicated cells analyzed using wound-healing/migration assay. The number of cells in the enclosure was enumerated at the indicated time points. (**f**) Effect of *KRT19* suppression on cell invasion assessed using CytoSelect 96-Wells Cell Invasion Assay Kit. Fluorescent intensities (RFUs) of the invading cells were plotted for control, scrambled shRNA (scramble), and shKRT19 MDA-MB231 and MCF7 cells. (**g**) Effect of *KRT19* knockdown on drug resistance measured by cell counting after 24 h of doxorubicin treatment (0.5 μ[M]{.smallcaps}). The mRNA expression level of drug-resistance marker genes was analyzed in the shKRT19 knockdown cells. (**h**) Cells were cultured in suspension in sphere-forming media (SFM) using non-coated plates. The number of spheres was counted on day 5. (**i**) mRNA expression levels of stemness marker genes were analyzed in the scramble and/or shKRT19 MDA-MB231 and MCF7 cells.
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###### 

Silencing of KRT19 expression upregulates the NOTCH signaling pathway by downregulating NUMB expression. Data were obtained from three independent experiments and presented as average values±s.d. (\**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001). (**a**) Expression levels of *WNT1*, CTNNB1, AXIN2, TCF7, LEF1, and *NUMB* were analyzed using RT--PCR. Bands were quantified by scanning densitometry and normalized to that of *GAPDH* (right panel). (**b**) The TOP-/FOP-Flash assays were evaluated using luciferase assay system. The indicated cells were transfected with TOP- or FOP-Flash plasmid, and then luciferase activity was measured. (**c**) Expression levels of *NOTCH1*, *MAML1*, *RBPjK*, *HES1*, *CCND1*, and *H-RAS* were analyzed using RT--PCR; protein levels of NICD, HES1, cyclinD1, H-RAS, and NUMB were assessed using western blotting (lower panel). Bands were quantified by scanning densitometry and normalized to that of *GAPDH* or actin (right panel). (**d**) Relative levels of *KRT19*, *NOTCH1*, and *NUMB* expression were analyzed in normal and invasive breast carcinomas using different Oncomine databases. Box, whiskers and asterisks reflect the interquartile range, 10--90% range, and the minimum or maximum values, respectively. Data are normalized facilitating inter-study comparison. The image was downloaded from the Oncomine datasets provided by Ma *et al.*,^[@bib15]^ Finak *et al.*,^[@bib38]^ Radvanyi *et al.*^[@bib39]^ or Zhao *et al.*^[@bib40]^
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###### 

DAPT treatment and NUMB overexpression help to overcome the effects of *KRT19* knockdown on proliferation, migration, invasion, and sphere formation in breast cancer cell lines. Data were obtained from three independent experiments and presented as average values±s.d. (\**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001). (**a**) Cell proliferation upon DAPT treatment (20 μ[M]{.smallcaps}) was analyzed by cell counting. Cells were counted up to 4 days. (**b**) Wound-healing/migration assay in DAPT-treated shKRT19 knockdown cells. Images were acquired at the indicated time points using bright-field microscopy (upper panel). The number of cells in the enclosure was counted (lower panel). (**c**) Invasiveness was analyzed in DAPT-treated shKRT19 knockdown cells. (**d**) The indicated cells were cultured in suspension in SFM using non-coated plates. The number of spheres was stained with crystal violet (upper panel), and counted (lower panel) on day 5. (**e**) Cell proliferation upon NUMB overexpression in shKRT19 cells was analyzed by cell counting. Cells were counted up to 4 days. (**f**) Wound-healing/migration assay was conducted in NUMB-overexpressed shKRT19 knockdown cells. Images were acquired at the indicated time points using bright-field microscopy (upper panel). The number of cells in the enclosure was counted (lower panel). (**g**) The indicated cells were cultured in suspension in SFM using non-coated plates. The number of spheres was stained with crystal violet (upper panel), and counted (lower panel) on day 5.
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![KRT19 regulates nuclear translocation of the β-catenin-RAC1 complex. (**a**) Levels of phospho (p)-AKT, AKT, p-GSK3β, and GSK3β analyzed in the indicated cells using western blotting. (**b**) β-catenin and RAC1 levels in cytosolic and nuclear fractions as analyzed by western blotting. c-JUN and actin were used as nuclear and cytoplasmic markers, respectively. (**c**) Subcellular localization of β-catenin and RAC1 monitored by immunocytochemistry. Scale bar represents 100 μm.](onc2016221f4){#fig4}

![KRT19 interacts with β-catenin and RAC1. (**a**) Lysates from the indicated cells were used for immunoprecipitation using Protein A/G Sepharose, antibodies specific for KRT19, β-catenin, and RAC1, and normal IgG. The immunoprecipitates were analyzed by western blotting with the antibodies indicated. For inputs, lysates were analyzed by western blotting with the indicated antibodies. (**b**) Immunoprecipitation conducted with the indicated antibodies using lysates from the indicated cells. For inputs, lysates were analyzed by western blotting with the indicated antibodies. (**c**) Cells were treated with MG132 and the protein levels of KRT19, β-catenin, and RAC1 were assessed by western blotting. (**d**) Immunoprecipitation assay was performed after MG132 treatment, using the antibodies indicated.](onc2016221f5){#fig5}

![Patient-derived CD133^high^/CXCR4^high^/ALDH1^high^ cancer stem-like cells (KU-CSLCs) show significantly decreased expression of KRT19 and highly enhanced CSLC properties. Data were obtained from three independent experiments and presented as average values±s.d. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001). (**a**) mRNA expression of *KRT19* analyzed by RNA sequencing in MDA-MB231 cells and KU-CSLCs. (**b**) Expression levels of *KRT19*, *NUMB, NOTCH1*, and *HES1* analyzed using reverse transcription polymerase chain reaction (RT--PCR) and western blotting. (**c** and **d**) Sphere-formation analysis in either growth (GM) or SFM medium using non-coated plates. Spheres from either MDA-MB-231 cells or KU-CSLCs were collected after 5 days of culture, stained with crystal violet (**c**) and counted (**d**). (**e** and **f**) mRNA expression levels of stemness (*OCT4*, *SOX2*, and *NANOG*) and epithelial-to-mesenchymal (EMT; N- and E-cadherin) markers analyzed using RT--PCR (**e**) and quantitative (qPCR) (**f**) in MDA-MB231 cells and KU-CSLCs cultured in either GM or SFM. (**g**) Representative images of the MDA-MB231- or KU-CSLC-injected SCID mice (left), and the excized tumors (right) 4 weeks post tumor formation (*n*=5). Tumor volume (mm^3^) (**h**) and weight (g) (**i**) assessed after biopsy. (**j**) Expression of *KRT19*, *NUMB*, *NOTCH1*, and *HES1* analyzed in the indicated cells after treatment with DAPT (20 μ[M]{.smallcaps}). (**k**) Proliferation of the indicated cells was assessed for 4 days after DAPT treatment. (**l**) Wound-healing/migration assay in control and DAPT-treated cells. The number of cells in the enclosure was enumerated at the time points indicated.](onc2016221f6){#fig6}

![Overexpression of *KRT19* or knockdown of *NOTCH1* leads to decreased CSLC properties in KU-CSLCs. Data were obtained from three independent experiments and presented as average values±s.d. (\**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001). (**a**) Expression of *KRT19*, *NUMB, NOTCH1*, and *HES1* analyzed in the *KRT19*-overexpressing or *NOTCH1*-knocked down KU-CSLCs using reverse transcription polymerase chain reaction (RT--PCR; upper panel). Protein levels of KRT19, NUMB, NICD, and HES1 were assessed by western blotting. (**b**) Proliferation of the indicated cells was assessed for 4 days. (**c**) Wound-healing/migration assay for the indicated cells. The number of cells in the enclosure was counted at the time points indicated. (**d**) Cell survival measured by cell counting after 24 h of treatment with doxorubicin (0.5 μ[M]{.smallcaps}) (upper panel) and expression of drug-resistance markers analyzed by RT--PCR (lower panel). (**e**) Sphere formation in SFM using non-coated plates. Spheres from the indicated cells were collected after 5 days of culture, stained with crystal violet (upper panel) and counted (lower panel). (**f**) Expression of stemness markers in the indicated cells.](onc2016221f7){#fig7}

![Schematic diagram depicting the KRT19-mediated regulation of NUMB expression, NOTCH signaling pathway and cancer/cancer stem-like cells (CSLC) properties in KRT19-overexpressing breast cancer cells. (**a**) KRT19 directly interacts with the β-catenin-RAC1 complex and stabilizes the ubiquitination and proteasomal degradation of β-catenin. This increases the nuclear translocation of β-catenin, enhancing *NUMB* expression in the process, which downregulates NOTCH signaling, its target genes, and consequently, cell proliferation, migration, invasion, drug resistance, and sphere formation. Patient-derived CD133^high^/CXCR4^high^/ALDH1^high^ KU-CSLCs, which showed significantly reduced *KRT19* expression, (**b**) displayed highly enhanced CSLC properties.](onc2016221f8){#fig8}

###### List of primers used for knockdown and overexpression of *KRT19* and *NOTCH1*, respectively

  *Accession no.*             *shRNA*               *Oligomers (5′--3′)*                               *Target site*
  ------------------------- ----------- --------------------------------------------- -----------------------------------------------
  NM_002276.4                 *KRT19*                AACCATGAGGAGGAAATCA                                 791--809
  NM_017617.3                *NOTCH1*                GTCCAGGAAACAACTGCAA                                 782--800
                             Scrambled            CCTAAGGTTAAGTCGCCCTCGCTC                             Non-specific
                                                                                                              
  *Plasmid name*              *Gene*                 *Forward (5′--3′)*                             *Reverse (5′--3′)*
  pGEMR-T easy vector         *KRT19*               CCTCGCCATGACTTCCTACA                           TCCCATCCCTCTACCCAGAA
  pCDH-EF1-MCS-T2A-copGFP     *KRT19*    CGC[tctaga]{.ul}CCTCGCCATGACTTCCTACA *Xba*I   CGC[gaattc]{.ul}GGAGGACCTTGGAGGCAGACA *EcoR*I

Underlined sequence is for restriction sites.

###### List of primers used for quantification of specific gene expression

  *Accession no.*            *Gene*     *Forward (5′--3′)*      *Reverse (5′--3′)*
  -------------------------- ---------- ----------------------- -------------------------
  NM_057088.2                *KRT3*     GAGCGGGAACAGATCAAGAC    TCCACTTGGTCTCCAGGACT
  NM_002272.3                *KRT4*     AGATACCTTGGGCAATGACA    CTTGTTCAGGTAGGCAGCAT
  NM_000424.3                *KRT5*     CACCAAGACTGTGAGGCAGA    CCTTGTTCATGTAGGCAGCA
  NM_005556.3                *KRT7*     CTCCGGAATACCCGGAATGAG   ATCACAGAGATATTCACGGCTCC
  NM_153490.2                *KRT13*    ACGCCAAGATGATTGGTTTC    CGACCAGAGGCATTAGAGGT
  NM_000224.2                *KRT18*    AGATCGAGGCTCTCAAGGAGG   CACGGTCAACCCAGAGCTG
  NM_002276.4                *KRT19*    GCGAGCTAGAGGTGAAGATC    CGGAAGTCATCTGCAGCCA
  NM_001005743.1             *NUMB*     TCCCACCTCTCCTACTTCTG    TGCCTCCCCTTCTACTTCTG
  NM_005430.3                *WNT1*     CTTCGGCCGGGAGTTCGTGG    CACCGTGCATGAGCCGGACA
  NM_001904.3                *CTNNB1*   AAAATGGCAGTGCGTTTAG     TTTGAAGGCAGTCTGTCGTA
  NM_004655.3                *AXIN2*    CTCCTTGGAGGCAAGAGC      GGCCACGCAGCACCGCTG
  NM_003202.3                *TCF7*     GACATCAGCCAGAAGCAAG     CACCAGAACCTAGCATCAAG
  NM_016269.4                *LEF1*     CCTGGTCCCCACACAACTG     GGCTCCTGCTCCTTTCTCTG
  NM_017617.3                *NOTCH1*   GGGTACAAGTGCGACTGTGA    CGGCAACGTCGTCAATACAC
  NM_014757.4                *MAML1*    CACCAGCCACCGAGTAACTT    AACAGGGAGTTCTGCTCGTG
  NM_005349.3                *RBPjK*    GAACAAATGGAACGCGATGG    GATGACTTTTATCCGCTTGCTG
  NM_005524.3                *HES1*     GGCTAAGGTGTTTGGAGGCT    GGTGGGTTGGGGAGTTTAGG
  NM_001130442.1             *H-RAS*    TTCTACACGTTGGTGCGTGA    CACAAGGGAGGCTGCTGAC
  NM_053056.2                *CCND1*    CACACGGACTACAGGGGAGT    ATGGTTTCCACTTCGCAGCA
  NM_002046.5                *GAPDH*    AATCCCATCACCATCTTCCAG   CACGATACCAAAGTTGTCATGG
                                                                 
  *Drug-resistance marker*                                      
   NM_004827.2               *ABCG2*    TTATCCGTGGTGTGTCTGGAG   TCCTGCTTGGAAGGCTCTATG
   NM_004996.3               *ABCC1*    GCCGGTGAAGGTTGTGTACT    CTGACGAAGCAGATGTGGAA
   NM_001163993.2            *ABCB5*    GAGAGACAGTCGCCTTGGTC    CCACGATTGTAGTCCGACCT
                                                                 
  *Stemness marker*                                             
   NM_001285986.1            *OCT4*     GTCCCAGGACATCAAAGCTC    CTCCAGGTTGCCTCTCACTC
   NM_003106.3               *SOX2*     ACACCAATCCCATCCACACT    GCAAGAAGCCTCTCCTTGAA
   NM_024865.3               *NANOG*    ATACCTCAGCCTCCAGCAGA    GCAGGACTGCAGAGATTCCT
   NM_002467.4               *c-MYC*    CTCGGATTCTCTGCTCTC      TCGCCTCTTGACATTCTC
